• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Janssen Pharmaceuticals

J&J expands it long-acting injectables partnership with Midatech

March 9, 2022 By Sean Whooley

Midatech Pharma (Nasdaq:MTP) announced today that it extended its R&D collaboration with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals. Cardiff, United Kingdom-based Midatech, a drug delivery technology company focused on the biodelivery and biodistribution of medicines, initially entered into the R&D collaboration with Janssen on July 21, 2020. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceutical, Research & Development Tagged With: Janssen Pharmaceuticals, Johnson & Johnson, Midatech Pharma

European regulators offer positive opinion on Janssen’s schizophrenia treatment

September 17, 2021 By Sean Whooley

Johnson & Johnson’s Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the positive opinion. The committee recommended using long-acting atypical antipsychotic Byannli (6-monthly paliperidone palmitate; PP6M) therapy for the maintenance treatment of schizophrenia. The recommendation […]

Filed Under: Clinical Trials, Drug-Device Combinations, Neurological, Pharmaceutical, Regulatory/Compliance Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

Janssen COVID-19 booster leads to nine-fold increase in neutralizing antibodies

August 25, 2021 By Brian Buntz

Johnson & Johnson (NYSE:JNJ) has announced that a booster of its viral-vector COVID-19 vaccine led to considerable increases in coronavirus spike-binding antibodies, according to interim data from two Phase 1/2 trials known as VAC31518COV1001 and VAC31518COV2001. In particular, the boosters led to a nine-fold increase in antibodies relative to levels 28 days after administering the prime […]

Filed Under: Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Janssen Pharmaceuticals, Johnson & Johnson, VAC31518COV1001, VAC31518COV2001

U.K. authorizes J&J COVID-19 vaccine

May 28, 2021 By Sean Whooley

The United Kingdom announced that it approved the single-dose COVID-19 vaccine developed by Johnson & Johnson’s Janssen Pharmaceutical business. The Medicines and Healthcare products Regulatory Agency (MHRA) granted the regulatory approval, making Janssen’s the fourth COVID-19 vaccine authorized by the independent regulator and the first to be approved as a single-dose option, according to a […]

Filed Under: Featured, Pharmaceutical, Regulatory/Compliance Tagged With: coronavirus, COVID-19, Janssen Pharmaceuticals, Johnson & Johnson

Pharma 50: Here’s how the world’s largest pharma companies are doing

May 12, 2021 By Chris Newmarker

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data […]

Filed Under: Business/Financial News, Featured, Pharmaceutical Tagged With: AstraZeneca, Gilead Sciences, GlaxoSmithKline plc, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer, Pharma 50, Roche, Sanofi, Sinopharm

How PhysIQ is advancing digital therapeutics through its partnership with Janssen

May 12, 2021 By Sean Whooley

A partnership with J&J’s Janssen Pharmaceuticals is helping PhysIQ advance with its device-agnostic clinical data collection and analysis platform.  Over the course of the last year and some change, the impact of digital health and the need for it has increased by an immeasurable amount. Virtual care became the norm after the COVID-19 pandemic hit, […]

Filed Under: Big Data, Biotech, Business/Financial News, Digital Health, Electronic Medical Records (EMR), Featured, Health Information Technology, Health Technology, Patient Monitoring, Pharmaceutical, Research & Development, Software / IT Tagged With: coronavirus, COVID-19, Janssen Pharmaceuticals, Johnson & Johnson, physiq

FDA, CDC lift pause on J&J COVID-19 vaccine

April 26, 2021 By Sean Whooley

The FDA and CDC have lifted the pause placed on the Johnson & Johnson (NYSE:JNJ) COVID-19 vaccine after reports of blood clots caused concern. On April 13, the FDA and CDC issued a joint statement recommending the pause in the administration of the J&J (Janssen) COVID-19 vaccine after, among 6.8 million doses delivered in the […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: Centers for Disease Control & Prevention (CDC), coronavirus, COVID-19, COVID-19 vaccine, FDA, Janssen Pharmaceuticals, Johnson & Johnson

PhysIQ, Janssen partner on digital therapeutics

April 20, 2021 By Sean Whooley

PhysIQ announced today that it is collaborating to license its AccelerateIQTM platform with Janssen Pharmaceuticals. Chicago-based PhysIQ’s AccelerateIQTM will be licensed to Janssen, a Johnson & Johnson unit so it can deploy it to collect data across its clinical studies through a range of its wearable biosensors, while also utilizing PhysIQ’s portfolio of FDA-cleared digital […]

Filed Under: Big Data, Business/Financial News, Electronic Medical Records (EMR), Featured, Health Technology, Software / IT Tagged With: Janssen Pharmaceuticals, Johnson & Johnson, physiq

Benefits of J&J COVID-19 vaccine outweigh risks, EU regulator says

April 20, 2021 By Sean Whooley

The European Medicines Agency confirmed that the benefits of the COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) outweigh risks of blood clots. At a meeting today, EMA’s safety committee (PRAC) concluded that there is a link between unusual blood clots with low blood platelets with the COVID-19 vaccine made by J&J’s Janssen Pharmaceuticals unit. PRAC determined that […]

Filed Under: Featured, Pharmaceutical, Regulatory/Compliance Tagged With: coronavirus, COVID-19, COVID-19 vaccine, Janssen Pharmaceuticals, Johnson & Johnson

FDA analysis finds J&J’s single-done COVID-19 vaccine is safe, effective

February 24, 2021 By Sean Whooley

An FDA analysis found that the single-dose COVID-19 vaccine candidate developed by Johnson & Johnson (NYSE:JNJ) is safe and effective. The analysis comes two days ahead of the FDA’s meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 26, 2021, to discuss the EUA request for the vaccine. Johnson & Johnson submitted the EUA […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccine trial, FDA, Janssen Pharmaceuticals, Johnson & Johnson

J&J submits EUL application to WHO for single-shot COVID-19 vaccine

February 19, 2021 By Sean Whooley

Johnson & Johnson (NYSE:JNJ) announced today that it submitted for emergency use listing (EUL) to the World Health Organization (WHO) for its COVID-19 vaccine. New Brunswick, N.J.-based J&J’s Janssen subsidiary’s single-dose COVID-19 vaccine candidate was submitted for EUL with a data package including interim efficacy and safety results from the Phase 3 Ensemble clinical trial, which […]

Filed Under: Clinical Trials, Featured, Pharmaceutical, Regulatory/Compliance Tagged With: coronavirus, COVID-19, COVID-19 vaccine, Janssen Pharmaceuticals, Johnson & Johnson, World Health Organization

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS